Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 2025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968 to Filter to 2025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968

---

Search results

• Journal article
  Maher TM, Tudor VA, Saunders P, Zanghelini F, Grossi Sampedro C, Xydopoulos G, Gibbons M, Fletcher SV, Denton CP, Kokosi M, Hoyles RK, Parfrey H, Renzoni EA, Wells AU, Ashby D, Fordham RJ, Szigeti M, Molyneaux PLet al., 2024,

  Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT

  , Efficacy and Mechanism Evaluation, Pages: 1-68, ISSN: 2050-4365

  <jats:sec id="abs1-1"><jats:title>Background</jats:title><jats:p>Interstitial lung disease frequently complicates systemic autoimmune disorders including scleroderma, idiopathic inflammatory myositis and mixed connective tissue disease, resulting in considerable morbidity and mortality. Based on the results of trials undertaken in scleroderma, cyclophosphamide is the standard of care for individuals with severe or progressive connective tissue disease-associated interstitial lung disease. Observational studies suggest that the anti-CD20 monoclonal antibody, rituximab is an effective rescue therapy in treatment of refractory connective tissue disease-associated interstitial lung disease, but it has not been studied as first-line therapy in clinical trials.</jats:p></jats:sec><jats:sec id="abs1-2"><jats:title>Objectives</jats:title><jats:p>To compare the safety and efficacy of rituximab against that of cyclophosphamide as treatment for individuals with severe, progressive interstitial lung disease associated with scleroderma, idiopathic inflammatory myositis or mixed connective tissue disease.</jats:p></jats:sec><jats:sec id="abs1-3"><jats:title>Methods</jats:title><jats:p>This was a Phase IIb, multicentre, randomised, double-blind, double-dummy study assessing the superiority of rituximab compared with cyclophosphamide, conducted in rheumatology or interstitial lung disease units at 11 UK centres. The study recruited individuals with extensive and/or progressive connective tissue disease-associated interstitial lung disease, excluding those with significant comorbidities, including airflow obstruction. Participants were randomised 1 : 1 to receive either rituximab 1 g given intravenously, twice at an interval of 2 weeks, or intravenous cyclophosphamide given monthly for 6 months at a dose of 600 mg/m<jats:sup>2</jats:sup> body surf

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Zhang C, de Pasquale S, Hartman K, Stanley CE, Berendsen RL, van der Heijden MGAet al., 2024,

  The microbial contribution to litter decomposition and plant growth

  , Environmental Microbiology Reports, Vol: 16, ISSN: 1758-2229

  Soil and plant roots are colonized by highly complex and diverse communities of microbes. It has been proposed that bacteria and fungi have synergistic effects on litter decomposition, but experimental evidence supporting this claim is weak. In this study, we manipulated the composition of two microbial kingdoms (Bacteria and Fungi) in experimental microcosms. In microcosms that were inoculated with fungi, litter loss was 47% higher than in microcosms that were not inoculated or only inoculated with bacteria. Combined inoculation with both bacteria and fungi did not significantly enhance decomposition compared with the fungi-only treatments, and, as such, we found no evidence for complementary effects using our experimental setup. Inoculation with fungi also had a positive impact on plant growth after 4 and 8 weeks (480% and 710% growth stimulation, respectively). After 16 weeks, plant biomass was highest in microcosms where both bacteria and fungi were present pointing to fungal-bacterial complementarity in stimulating plant growth. Overall, this study suggests that fungi are the main decomposers of plant litter and that the inoculated fungi contribute to plant growth in our experimental system.

  • Abstract
  • Publisher Web Link
  • Open Access Link
  • Cite
• Journal article
  Arraiano-Castilho R, Bidartondo MI, Niskanen T, Brunner I, Zimmermann S, Senn-Irlet B, Frey B, Peintner U, Mrak T, Suz LMet al., 2024,

  Climatic shifts threaten alpine mycorrhizal communities above the treeline

  , FUNGAL ECOLOGY, Vol: 67, ISSN: 1754-5048
  • Cite
• Journal article
  Mayer F, Prado-Roller A, Mautner A, Bismarck Aet al., 2024,

  Retain strength, gain ductility: tough and transparent nanopapers by mercerisation

  , CELLULOSE, Vol: 31, Pages: 1533-1544, ISSN: 0969-0239
  • Cite
• Journal article
  Moriyama H, Kotta-Loizou I, Kim K-H, 2024,

  Editorial: Community series in mycoviruses and related viruses infecting fungi, lower eukaryotes, plants and insects, volume II

  , Frontiers in Microbiology, Vol: 15, ISSN: 1664-302X
  • Author Web Link
  • Open Access Link
  • Cite
• Journal article
  Lord JM, Veenith T, Sullivan J, Sharma-Oates A, Richter AG, Greening NJ, McAuley HJC, Evans RA, Moss P, Moore SC, Turtle L, Gautam N, Gilani A, Bajaj M, Wain LV, Brightling C, Raman B, Marks M, Singapuri A, Elneima O, Openshaw PJM, Duggal NA, PHOSP-COVID Study collaborative group, ISARIC4C investigatorset al., 2024,

  Accelarated immune ageing is associated with COVID-19 disease severity

  , Immunity and Ageing, Vol: 21, ISSN: 1742-4933

  BACKGROUND: The striking increase in COVID-19 severity in older adults provides a clear example of immunesenescence, the age-related remodelling of the immune system. To better characterise the association between convalescent immunesenescence and acute disease severity, we determined the immune phenotype of COVID-19 survivors and non-infected controls. RESULTS: We performed detailed immune phenotyping of peripheral blood mononuclear cells isolated from 103 COVID-19 survivors 3-5 months post recovery who were classified as having had severe (n = 56; age 53.12 ± 11.30 years), moderate (n = 32; age 52.28 ± 11.43 years) or mild (n = 15; age 49.67 ± 7.30 years) disease and compared with age and sex-matched healthy adults (n = 59; age 50.49 ± 10.68 years). We assessed a broad range of immune cell phenotypes to generate a composite score, IMM-AGE, to determine the degree of immune senescence. We found increased immunesenescence features in severe COVID-19 survivors compared to controls including: a reduced frequency and number of naïve CD4 and CD8 T cells (p < 0.0001); increased frequency of EMRA CD4 (p < 0.003) and CD8 T cells (p < 0.001); a higher frequency (p < 0.0001) and absolute numbers (p < 0.001) of CD28-ve CD57+ve senescent CD4 and CD8 T cells; higher frequency (p < 0.003) and absolute numbers (p < 0.02) of PD-1 expressing exhausted CD8 T cells; a two-fold increase in Th17 polarisation (p < 0.0001); higher frequency of memory B cells (p < 0.001) and increased frequency (p < 0.0001) and numbers (p < 0.001) of CD57+ve senescent NK cells. As a result, the IMM-AGE score was significantly higher in severe COVID-19 sur

  • Abstract
  • Publisher Web Link
  • Author Web Link
  • Open Access Link
  • Cite
• Conference paper
  Baltas I, Kavallieros K, Konstantinou G, Koutoumanou E, Gibani MM, Gilchrist M, Davies F, Pavlu Jet al., 2024,

  The effect of ciprofloxacin prophylaxis during haematopoietic cell transplantation on infection episodes, exposure to treatment antimicrobials and antimicrobial resistance: a single-centre retrospective cohort study

  , Publisher: OXFORD UNIV PRESS
  • Cite
• Conference paper
  Schaubeder JB, Biegler V, Spirk S, Hirn U, Nypelö T, Bismarck A, Bauer Wet al., 2024,

  Role of xylan in softwood kraft pulp fiber sheets and fiber foams

  Pulp fibers are paramount in paper products. However, they have lately also seen emerging use in fiber foams. Xylans, that are integral in pulp fibers are known to contribute to the strength of paper. However, if what is known about strength of paper, applies to strength of fiber foams, has not been elucidated. In this contribution we investigated the role played by xylan hand sheets and foams. We removed enzymatically 1% and added by adsorption 3% xylan on fibers corresponding to approximately a decrease of a tenth and an increase of a third of the total xylan content. The mechanical properties increased for sheets made using the xylan enriched pulp, however, the decrease in mechanical properties for the enzyme treated pulp was more pronounced. For networks with lower fiber-fiber contacts, that is, in foams, the mechanical properties were not as much influenced by the removal of xylan. The adsorption of additional xylan, on the other hand, increased the compressive strength of the fiber networks significantly. We propose that the improvement of mechanical properties for the sheets results from a combination of increased number of fiber-fiber bonds and higher sheet density, while the deterioration in mechanical properties of the enzyme treated fibers is caused by the opposite effect. In foams, the effect of density should not play such a significant role and hence the enzymatic treatment did not affect the mechanical properties as much. These findings suggest that xylan is a key component in strengthening the internal bonds in sheets and in foam although the underlying mechanisms may be different.

  • Abstract
  • Cite
• Journal article
  Guillen-Guio B, Paynton ML, Allen RJ, Chin DPW, Donoghue LJ, Stockwell A, Leavy OC, Hernandez-Beeftink T, Reynolds C, Cullinan P, Martinez F, Booth HL, Fahy WA, Hall IP, Hart SP, Hill MR, Hirani N, Hubbard RB, McAnulty RJ, Millar AB, Navaratnam V, Oballa E, Parfrey H, Saini G, Sayers I, Tobin MD, Whyte MKB, Adegunsoye A, Kaminski N, Ma S-F, Strek ME, Zhang Y, Fingerlin TE, Molina-Molina M, Neighbors M, Sheng XR, Oldham JM, Maher TM, Molyneaux PL, Flores C, Noth I, Schwartz DA, Yaspan BL, Jenkins RG, Wain LV, Hollox EJet al., 2024,

  Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis

  , ERJ OPEN RESEARCH, Vol: 10
  • Cite
• Journal article
  Dixon G, Hague S, Mulholland S, Adamali H, Khin AMN, Thould H, Connon R, Minnis P, Murtagh E, Khan F, Toor S, Lawrence A, Naqvi M, West A, Coker RK, Ward K, Yazbeck L, Hart S, Garfoot T, Newman K, Rivera-Ortega P, Stranks L, Beirne P, Bradley J, Rowan C, Agnew S, Ahmad M, Spencer LG, Aigbirior J, Fahim A, Wilson AM, Butcher E, Chong SG, Saini G, Zulfikar S, Chua F, George PM, Kokosi M, Kouranos V, Molyneaux P, Renzoni E, Vitri B, Wells AU, Nicol LM, Bianchi S, Kular R, Liu HJ, John A, Barth S, Wickremasinghe M, Forrest IA, Grimes I, Simpson AJ, Fletcher S, Jones MG, Kinsella E, Naftel J, Wood N, Chalmers J, Crawshaw A, Crowley LE, Dosanjh D, Huntley CC, Walters G, Gatheral T, Plum C, Bikmalla S, Muthusami R, Stone H, Rodrigues JCL, Tsaneva-Atanasova K, Scotton CJ, Gibbons MA, Barratt SLet al., 2024,

  Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK

  , ERJ OPEN RESEARCH, Vol: 10
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.